Sionna missed the key activity endpoint for the SION-719 proof-of-concept trial, canceling development as an add-on to Trikafta. Despite the setback, the company maintains strong cash reserves and advanced its NBD1 dual combination trial.
Sionna missed the key activity endpoint for the SION-719 proof-of-concept trial, canceling development as an add-on to Trikafta. Despite the setback, the company maintains strong cash reserves and advanced its NBD1 dual combination trial.